Nanoform CTO Niklas Sandler transitions to technology advisor to the CEO
Company release
Nanoform Finland Plc
December 20th, 2022
15:05 Finnish time / 14:05 Swedish time
Nanoform CTO Niklas Sandler transitions to technology advisor to the CEO
Helsinki, Finland – Niklas Sandler will transition January 1st, 2023, from his role as Chief Technology Officer (CTO) to technology advisor to the CEO of Nanoform. This coincides with Nanoform’s growth strategy moving from an R&D led organization to a commercial and industrial business and Niklas’ ambition to become an entrepreneur as founder and Chief Scientific Officer (CSO) in developing CurifyLabs, which is based on his previous academic research in 3D printing technologies.
“I would like to thank Edward and all Nanoformers for our fantastic journey together. It has been highly rewarding to see Nanoform’s technology mature into a successful commercial offering for the pharma industry. I’m very grateful for the opportunity to continue as technology advisor to the CEO“, said Niklas Sandler.
“I thank Niklas for his excellent work contribution and look forward to continue to work with him in his new capacity”, said Edward Hæggström.
For further information, please contact:
Edward Hæggström, CEO
edward.hæggströ[email protected] / +358 29 370 0150
For investor relations queries, please contact:
Henri von Haartman, Director of Investor Relations
[email protected] / +46 7686 650 11
About Nanoform
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform’s platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services. Nanoform’s capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information, please visit www.nanoform.com.
Forward-Looking Statements
This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform’s strategy, business plans and focus. The words may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform’s business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks described in the Report of the Board of Directors and Financial Statements for the year ended December 31, 2021 as well as our other past disclosures. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Nanoform’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
